OncoMouse — The First Patented Animal, Built to Get Cancer
Philip Leder and Timothy Stewart's 1988 DuPont/Harvard patent on the OncoMouse describes the first genetically engineered animal ever patented — a mouse with an activated cancer gene, used to test cancer drugs.
Original patent title: “Transgenic non-human mammals”
What this patent covers
The actual claim
This patent covers a transgenic non-human mammal (specifically, a mouse) that has been genetically modified to carry an activated oncogene — a gene that causes cancer to develop. The oncogene is introduced into the mouse's fertilized egg using recombinant DNA techniques, so that every cell in the resulting animal carries the cancer-promoting gene. Because the oncogene is heritable, offspring of these mice also carry it, allowing researchers to produce consistent experimental animals for cancer research. The mice are predisposed to develop tumors at predictable rates and locations, making them far more useful as cancer research models than randomly induced tumors.
What this patent does NOT cover
The boundaries
- The specific genetic technique (recombinant DNA/transgenic methods) — those are covered by separate foundational patents
- Other transgenic animals beyond non-human mammals — later patent applications for fish, insects, and plants required separate proceedings
- Human genetic modification — the patent explicitly covers non-human mammals; human germline editing remains unpatentable and illegal in most jurisdictions
- Specific cancer drugs or treatments — the mouse is a research tool, not a therapy
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
What made this novel
The OncoMouse patent was the culmination of a decade-long debate: could an animal — a living thing — be patented? The 1980 Diamond v. Chakrabarty Supreme Court case had allowed patents on genetically modified bacteria ('anything under the sun made by man'), but animals were assumed to be different. The U.S. Patent and Trademark Office initially rejected Harvard's application on the grounds that animals were products of nature. After appeals and years of consideration, the USPTO granted the patent in 1988 — the first ever for a vertebrate animal. The mouse itself was engineered to carry the myc oncogene, one of the most studied cancer-promoting genes. DuPont commercialized it and charged cancer researchers licensing fees, which generated significant controversy in academia.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
The OncoMouse was used in thousands of cancer research studies throughout the 1990s and 2000s — it became the standard animal model for breast cancer research
DuPont licensed the mouse to academic researchers under controversial 'reach-through' agreements claiming royalties on any discoveries made using it
Canada's Supreme Court refused to extend the patent to Canada in 2002, ruling 5-4 that higher life forms are not patentable under Canadian law — the same mouse was simultaneously patented in the U.S. and unpatentable in Canada
Why it matters
The bigger picture
The OncoMouse patent fundamentally changed the relationship between academic research and intellectual property. Before it, research tools — cell lines, antibodies, genetic sequences — were generally shared freely. After it, universities and corporations began aggressively patenting biological research tools. The resulting licensing fees and 'reach-through' royalty demands on research findings created a significant controversy about whether patents on living organisms help or harm scientific progress. The patent expired in 2005, and today transgenic mice are standard research tools available from commercial suppliers. The OncoMouse's legal legacy — the patentability of genetically modified organisms — continues to shape biotechnology IP law.
Filed
June 22, 1984
Granted
April 12, 1988
Claim 1 — Plain English
What this patent covers
This patent covers a transgenic non-human mammal (specifically, a mouse) that has been genetically modified to carry an activated oncogene — a gene that causes cancer to develop. The oncogene is introduced into the mouse's fertilized egg using recombinant DNA techniques, so that every cell in the resulting animal carries the cancer-promoting gene. Because the oncogene is heritable, offspring of these mice also carry it, allowing researchers to produce consistent experimental animals for cancer research. The mice are predisposed to develop tumors at predictable rates and locations, making them far more useful as cancer research models than randomly induced tumors.
The clever bit
The OncoMouse patent was the culmination of a decade-long debate: could an animal — a living thing — be patented? The 1980 Diamond v. Chakrabarty Supreme Court case had allowed patents on genetically modified bacteria ('anything under the sun made by man'), but animals were assumed to be different. The U.S. Patent and Trademark Office initially rejected Harvard's application on the grounds that animals were products of nature. After appeals and years of consideration, the USPTO granted the patent in 1988 — the first ever for a vertebrate animal. The mouse itself was engineered to carry the myc oncogene, one of the most studied cancer-promoting genes. DuPont commercialized it and charged cancer researchers licensing fees, which generated significant controversy in academia.
What it does not cover
- The specific genetic technique (recombinant DNA/transgenic methods) — those are covered by separate foundational patents
- Other transgenic animals beyond non-human mammals — later patent applications for fish, insects, and plants required separate proceedings
- Human genetic modification — the patent explicitly covers non-human mammals; human germline editing remains unpatentable and illegal in most jurisdictions
- Specific cancer drugs or treatments — the mouse is a research tool, not a therapy
Patent Journey
From filing to expiry
Patent Filed
1984
Patent Granted
1988 · 4yr after filing
Highly Cited
643 patents cite this
Patent Expired
2004
PatentBrief Score
Impact Score
Moderate
Citation count
40/40
Highly cited
Claim breadth
9/20
Moderate scope
Recency
0/20
Older than 20 years
Assignee scale
0/20
Independent or smaller assignee
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
The original legal language
Original claims
13 claims as filed with the patent office.
Glossary
Key terms defined
- oncogene
- A gene that, when mutated or overexpressed, promotes the development of cancer — the myc gene in OncoMouse is one of the most studied
- transgenic
- An organism that has had foreign DNA (from another species or artificially synthesized) inserted into its genome
- recombinant DNA
- DNA formed by combining sequences from different organisms using molecular biology techniques — the foundation of genetic engineering
Citations
Patent lineage
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 12564871 · 2026
A Fixture for Cleaning Showerheads with Multiple Separate Chambers
This patent describes a cleaning device for showerheads that uses a fixture with three or more separate internal compartments and channels to direct cleaning fluid to the showerhead's upper surfaces.
ASM IP HOLDING BV
US 12324579 · 2025
Surgical Stapler Battery Health Check During Operation
This patent describes a powered surgical stapler that can detect if some of its rechargeable battery cells are damaged while it's actually firing staples, helping ensure the procedure finishes safely.
CILAG GMBH INT
US 12471982 · 2025
Surgical Tool That Combines Energy Treatment and Stapling
CILAG's patent details a surgical instrument that applies therapeutic energy to tissue, monitors its properties, then deploys staples, adapting the stapling based on the initial energy treatment and monitoring.
CILAG GMBH INT
US 11918209 · 2024
Real-Time Surgical Instrument Status on Live Video During Operations
This patent describes a surgical system that shows live video from inside the body and overlays important information about the surgical tool directly onto the screen, helping surgeons operate more precisely.
CILAG GMBH INT
US 8697359 · 2014
How to Use CRISPR-Cas9 to Edit Genes in Human Cells
This patent describes a method and system for precisely altering gene expression in eukaryotic cells, including human cells, using an engineered CRISPR-Cas9 system that targets and cleaves specific DNA sequences.
Massachusetts Institute of Technology
US 4683195 · 1987
How to Make Many Copies of a Specific DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a fundamental process for making millions of copies of a specific DNA or RNA segment from a tiny sample, enabling its detection.
Cetus Corp
Semantically similar
You might also find these interesting
US 4237224 · 1980 · Leland Stanford Junior University
How to Make Hybrid DNA and Grow It in Microbes
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Use CRISPR-Cas9 to Edit Genes in Human Cells
US 3789832 · 1974
MRI — The Imaging Machine That Detects Cancer Without Radiation
US 4683195 · 1987 · Cetus Corp
How to Make Many Copies of a Specific DNA Segment
Patent monitoring